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List of abbreviations 
AD: Alzheimer’s disease 
CD: Crohn’s disease 
EGTA: ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid 
ENS: Enteric nervous system 
GFAP: Glial fibrillary acidic protein 
GI: Gastrointestinal 
MAPT: Microtubule-associated protein tau 
NDP52: Nuclear dot protein 52 kDa 
Nrf2: Nuclear factor erythroid 2-related factor 
PAGE: Polyacrylamide gel electrophoresis 
PD: Parkinson’s disease 
PSP: Progressive supranuclear palsy  
RPS6: Ribosomal protein S6 
SDS: Sodium dodecyl sulfate 
SNCA: Synuclein alpha 
TBS: Tris buffered saline 
UC: Ulcerative colitis 
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Abstract 
A sizeable body of evidence has recently emerged to suggest that gastrointestinal 
inflammation might be involved in the development of Parkinson’s disease. There is now 
strong epidemiological and genetical evidence linking Parkinson's disease to inflammatory 
bowel diseases and we recently demonstrated that the neuronal protein alpha-synuclein, 
which is critically involved in Parkinson’s disease pathophysiology, is upregulated in inflamed 
segments of Crohn’s colon. The microtubule associated protein tau is another neuronal 
protein critically involved in neurodegenerative disorders but, in contrast to alpha-synuclein, 
no data are available about its expression and phosphorylation patterns in inflammatory 
bowel diseases. Here, we examined the expression levels of tau isoforms, their 
phosphorylation profile and truncation in colon biopsy specimens from 16 Crohn’s disease 
and 6 ulcerative colitis patients and compared them to samples from 16 controls. Additional 
experiments were performed in full thickness segments of colon of 5 Crohn’s disease and 5 
control subjects, in primary cultures of rat enteric neurons and in Nrf2 knockout mice. Our 
results show the upregulation of two main human tau isoforms in the enteric nervous 
system in Crohn’s disease but not in ulcerative colitis. This upregulation was not 
transcriptionally regulated but instead likely resulted from a decrease in protein clearance 
via an Nrf2 pathway. Our findings, which provide the first detailed characterization of tau in 
Crohn’s disease, suggest that the key proteins involved in neurodegenerative disorders such 
as alpha-synuclein and tau, might also play a role in Crohn’s disease. 
  
 4 
Introduction 
Crohn’s disease (CD) is a type of inflammatory bowel disease, which is characterized by 
chronic remitting and relapsing inflammation of the entire gastrointestinal (GI) tract. 
Although the precise etiology of CD is unknown, it is generally accepted that it develops 
through an exaggerated immune response to luminal antigens in genetically susceptible 
individuals leading to intestinal epithelium inflammation and damage (1). The pathological 
process in CD is however not limited to the epithelial lining but extends to all components of 
the GI wall including the enteric nervous system (ENS) whose structure and neurochemical 
phenotype are altered during active CD (2). The major structural abnormalities thus far 
described in CD include architectural alterations of the plexuses, nerve hypertrophy and 
hyperplasia along with alterations of neuronal cell bodies (3, 4). Regarding neurochemical 
phenotype, the two most comprehensive studies found an increased number of vasoactive 
intestinal polypeptide‐immunoreactive nerve cell bodies in both the myenteric and 
submucosal plexuses (5, 6).  
The ENS structure and neurochemistry resemble that of the CNS, therefore 
pathogenic mechanisms that give rise to CNS disorders might also lead to ENS dysfunction, 
and vice versa (7). Over the past two decades, progress in molecular genetics and 
neuropathology enabled a better understanding of the pathogenesis of neurodegenerative 
disorders. The observation that abnormal protein accumulation is characteristic of particular 
disease sets has led to a neuropathological classification according to the composition of the 
abnormal protein aggregates. The most common neurodegenerative disorders are now 
classified based on the abnormal accumulation of alpha-synuclein (8) or tau (9) and hence 
referred to as synucleinopathies (with Parkinson’s disease (PD) being the prototypical type) 
or tauopathies (with Alzheimer’s disease (AD) being the most common), respectively (10, 
11). It should be noted however that the pathological distinction among these disorders is 
sometimes not so clear as the co-occurrence of alpha-synuclein and tau deposits has been 
reported in PD (12). Several independent studies have shown that enteric neurons, like their 
CNS counterparts, also express alpha-synuclein (13–15) and tau (16, 17) and we recently 
demonstrated that alpha-synuclein is upregulated in inflamed segments of Crohn’s colon 
(18). These latter findings, together with the results of recent epidemiological (19, 20) and 
genetical studies (21), support the existence of a close relationship between Parkinson’s and 
Crohn’s disease. In contrast to alpha-synuclein, no data are available about the expression 
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and phosphorylation patterns of enteric tau in CD. Here, we examined the expression levels 
of tau isoforms, their phosphorylation profile and truncation in colon biopsy specimens from 
CD patients and compared them to samples from controls. Additional experiments were 
performed in primary cultures of rat enteric neurons and in Nrf2 knockout mice. Our results 
show the upregulation of two main human tau isoforms in the ENS in CD, which results from 
a decrease in protein clearance via an Nrf2 pathway. Our findings, which provide the first 
detailed characterization of tau in CD, suggest that the key proteins involved in 
neurodegenerative disorders such as alpha-synuclein and tau, might also play a role in CD, 
and provide mechanistic insights into the events underlying tau and alpha-synuclein 
accumulation in CD gut. 
 
Material and methods 
Participants and human tissues 
A total of 38 subjects participated in this study, 16 CD and 6 ulcerative colitis (UC) patients as 
well as 16 healthy controls who had a normal colonoscopy for colorectal cancer screening 
(All 6 UC patients, 10/16 CD patients and 10/16 controls from the current study had their 
biopsies previously analyzed in (18) for the expression levels of alpha-synuclein). The study 
protocol was approved by the local Committee on Ethics and Human Research (Comité de 
Protection des Personnes Ouest VI). Written informed consent was obtained from each 
patient and from each normal volunteer before the endoscopic procedure. All procedures 
were performed according to the guidelines of the French Ethics Committee for Research on 
Humans and registered under the no. DC-2008-402. CD and UC patients had 4 routine 
biopsies (2 in an inflamed and 2 in a non-inflamed area) taken during the course of a 
colonoscopy and stored in RA1 buffer (Macherey Nagel, Hoerdt, France) until further 
analysis. For controls, 6 routine biopsies were taken and also stored in RA1 buffer (22). The 
inflammatory status of CD and UC biopsies was confirmed by qPCR for TNF- and IL1-
(Figure S1A). 
Samples from 5 additional CD patients and 5 controls were used for 
immunohistochemistry and sarkosyl extraction experiments. FFPE full thickness segments of 
colon containing the myenteric plexus were obtained from 3 CD patients and 3 controls 
subjects who underwent colonic resection for disease management and non-obstructive 
colorectal carcinoma, respectively were used for IHC experiments. Frozen full thickness 
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segments of colon from two additional CD patients and two controls were used for sarkosyl 
extraction experiments. For all control tissues, sampling was performed in macroscopically 
normal segments of uninvolved resection margins. 
Samples of frozen temporal cortex from two post-mortem human brains, one with 
AD and one devoid of neurodegeneration were obtained from the Neuropathology 
Department of Angers (Dr Franck Letournel) to serve as a control is sarkosyl extraction 
experiments. 
 
Primary culture of rat ENS 
Primary cultures of rat ENS were generated and cultured as previously described (23). Cells 
were treated with 10 µM sulforaphane or MG132 (both from Sigma, Saint-Quentin-Fallavier, 
France) for 12h. 
 
Knockout mice 
Nrf2−/− mice were provided by the RIKEN BRC according to an MTA to Prof S. Kerdine-
Römer  (24). Mice were housed in a pathogen-free facility and handled in accordance with 
the principles and procedures outlined in Council Directive 86/609/EEC. Genotyping was 
performed by PCR using genomic DNA that was isolated from tail snips as described (24).  
 
Western Blot 
Two biopsies per patient stored in RA1 buffer were pooled and lysed using the “Precellys 24” 
tissue homogenizer (Bertin technologies, St Quentin-en-Yvelines, France) followed by 
sonication with “vibracell 75 186” device (Sonics, Newton CT, USA). Protein and RNA 
extractions were performed with NucleoSpin Triprep Kit (Macherey‐Nagel). The total 
proteins were precipitated and prepared for PAGE using protein precipitator and 
resuspension buffer PSB/TCEP (Protein solving buffer and (tris(2-carboxyethyl)phosphine) 
TCEP reducing agent) from the NucleoSpin Triprep Kit. The elution fraction containing RNA 
was further used for PCR analysis (see below). Cells (primary culture of rat ENS) and tissues 
from mice (distal colon) were lysed in RIPA lysis buffer (Merck Millipore, Fontenay sous Bois, 
France) containing phosphatase inhibitor cocktail II (Sigma) and protease inhibitors cocktail 
(Roche, Neuilly sur Seine, France). Equal amounts of tissue or cell lysates were separated 
and analyzed by Western blot as previously described (18). Tau protein ladder (Sigma) was 
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used in some experiments as a control. The primary antibodies used are listed in Table 1. 
Mouse monoclonal anti-PGP 9.5 antibody was used as a pan-neuronal marker (Table 1) and 
membranes were reprobed with mouse monoclonal anti-β-actin antibody (Table 1) to 
confirm equal protein loading. For quantification, the relevant immunoreactive bands were 
quantified with laser-scanning densitometry and analyzed with NIH Image J software. To 
allow comparison between different films, the density of the bands was expressed as a 
percentage of the average of controls. 
 
Immunohistochemistry 
Fixed human tissues from 3 CD patients and 3 controls were included in paraffin using an 
embedding station (MICROM MICROTECH STP120, Brignais, France) and sections (5µm) were 
performed using a microtome (MICROM HM355S). Immunohistochemistry was performed 
as described previously (18) using the primary antibodies listed in table 1. For quantification, 
analyses were performed with the ImageJ software (NIH, Bethesda, MD). Fluorescence 
immunohistochemical signals were recorded from each specimen of the control and CD 
group respectively. Each myenteric ganglion was marked and the mean grey value 
(integrated density/μm2 ganglionic tissue) was determined. 
 
Sarkosyl extraction and ultracentrifugation 
For sarkosyl extraction of tau, tissues were homogenized in 50 mM Tris-buffered saline (TBS, 
pH 7.4) containing 2 mM EGTA, 1 mM Na3VO4, 10 mM sodium fluoride, 1 mM 
phenylmethylsulfonyl fluoride and 10 % (w/v) sucrose (all from Sigma). Samples were 
centrifuged at 12,000 g for 20 min at 4 °C to remove cells debris and 10% (v/v) sarkosyl was 
added to the resultant supernatant to give a final concentration of 1% (v/v). Samples were 
mixed for 30 min at room temperature (20°C), then centrifuged at 100,000 g for 1 h at 20°C. 
The supernatant (sarkosyl-soluble tau) was collected and the pellet (sarkosyl-insoluble tau) 
was washed twice with 1% (v/v) sarkosyl. Proteins in the samples were resolved by PAGE 
and processed for immunoblotting as described in the Western Blot section.  
 
RT-PCR 
RNA extraction was performed with NucleoSpin Triprep Kit (Macherey‐Nagel) in two-pooled 
biopsies (see Western Blot section). One μg purified mRNA was denatured and processed for 
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reverse transcription using Superscript III reverse transcriptase (Thermo Fisher Scientific, 
Saint‐Herblain, France). PCR amplifications were performed using the Absolute Blue SYBR 
green fluorescein kit (Roche) and run on a StepOnePlus system (Thermo Fisher). The 
following primers were used: MAPT, forward: 5’AGAGTCCAGTCGAAGATTGGGTC3’; reverse: 
5’GGGTTTCAATCTTTTTATTTCCTCC3’. SNCA, forward: 5’CCAAAGAGCAAGTGACAAATGTTG3’; 
reverse: 5’AGCCAGTGGCTGCTGCAAT3’. TNF-α, forward: 5’CCCGAGTGACAAGCCTGTAG3’; 
reverse: 5’TGAGGTACAGGCCCTCTGAT3’. IL-1β, forward: 5’GAGCAACAAGTGGTGTTCTCC3’; 
reverse: 5’TTGGGATCTACACTCTCCAGC3’. RPS6, forward: 5’AAGCACCCAAGATTCAGCGT3’; 
reverse: 5’TAGCCTCCTTCATTCTCTTGGC3’; 
 
Statistics 
All data shown are mean ± SEM. Statistical analyses were performed using GraphPad 
software version 8.00 (San Diego California, USA). Between-group comparisons were 
performed using an independent sample t test (Mann-Whitney test), Kruskal-Wallis or Chi-
squared test. For association between two variables, Spearman’s correlation was performed. 
Differences were deemed statistically significant when p<0.05. 
 
Results 
The main clinical features of the study population are shown in Figure S1B. CD patients were 
significantly younger than controls (Figure S1B). 
 
Tau expression is increased in Crohn’s disease but not in ulcerative colitis 
We first analyzed the expression levels of tau in colonic biopsies of CD and controls by 
Western blot. A significant 8- and 4-fold increase in tau protein expression was observed in 
the inflamed area of CD patients when compared to controls, after normalization to PGP 9.5 
and -actin, respectively (Figure 1A and Figure S2). By contrast, no significant differences 
were observed when the non-inflamed area was compared to controls (Figure 1A and Figure 
S2) and when biopsies of UC patients, either in the inflamed or non-inflamed area were 
compared to controls (Figure S2). There were no correlations between the expression levels 
of tau, age and disease duration (Figure S2). We have recently shown that 1N3R and 0N4R 
are the two main tau isoforms expressed in the adult human ENS and that these two 
isoforms are phosphorylated under physiological conditions (16). Using 3R and 4R isoform 
 9 
specific antibodies, we found that both 1N3R and 0N4R tau isoforms were upregulated in 
the inflamed area in CD (Figure 1B). We next examined the phosphorylation state of tau with 
a phospho-specific antibody that detect tau phosphorylated at Ser396. After normalizing to 
total tau, the amount of phosphorylated tau was not different between CD samples and 
controls (Figure 1C and Figure S2). Truncated tau is present in the pathological deposits 
observed in CNS tauopathies, including progressive supranuclear palsy (PSP) and Alzheimer’s 
disease (25). In order to determine whether tau is C-terminally truncated in the enteric 
neurons in CD, colonic biopsies were analyzed using a monoclonal antibody that specifically 
recognizes tau cleaved at Asp421 by caspase-3. After normalizing to total tau, the amount of 
truncated tau was dramatically decreased in CD inflamed area when compared to either 
non-inflamed area or controls (Figure 1D and Figure S2). Additional immunohistochemistry 
experiments were performed to examine the localization and the expression levels of tau in 
the myenteric plexus. Colonic myenteric plexus showed intense tau immunoreactivity in 
both neuronal cell bodies and processes, which nearly completely overlapped beta-tubulin 
immunostaining (Figure 2A). Quantification of the immunofluorescence showed increased 
tau immunoreactivity in CD myenteric plexus as compared to controls (Figure 2B). When 
taken together, these results show that tau expression is increased in both the submucosal 
and myenteric plexus in CD, without changes in its phosphorylation status. In addition, and 
despite the relatively small sample size of UC patients, our findings also suggest that unlike 
CD the expression levels of tau are unaltered in UC. 
 
The upregulation of tau in Crohn’s disease is not accompanied with more insoluble or 
oligomeric forms of the protein 
Tau cleaved by caspase-3 at Asp421 is more prone to aggregation and acts as a nidus for 
aggregation of full-length tau (26, 27). To examine whether tau upregulation is associated 
with protein aggregation, we used T22, a recently developed tau oligomer-specific antibody 
(28). As expected, this antibody detected slower migrating tau bands in AD brain when 
compared to control brain (Figure S3A). However, no difference in the banding pattern was 
observed when this antibody was used to compare biopsy lysates from CD and controls 
(Figure S3B). In CNS tauopathies, the biochemical characterization of pathological tau 
involves well-standardized protocols  based on the use of sarkosyl (29)(Figure S3C). Using 
this method along with the T22 antibody, we showed that the levels of sarkosyl-insoluble tau 
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was increased in AD when compared to control brain (Figure S3D). In contrast, no sarkosyl-
insoluble tau was detected in the GI tract samples from either CD patients or control 
subjects (Figure S3D). These data suggest that tau upregulation in CD is not associated with 
more aggregation. 
 
Tau upregulation in Crohn’s disease is specific as not observed for MAP2c, III-tubulin and 
synapsin I 
To determine whether the upregulation of tau is specific to this microtubule associated 
protein, we analyzed the expression levels of its sequence homologue MAP2c along with 
two of its interacting proteins, III-tubulin and synapsin I (30, 31). Unlike tau, the amounts of 
MAP2c and III-Tubulin were not different between CD and controls (Figure 3). By contrast, 
synapsin I expression was significantly decreased in samples of CD colon when compared to 
controls (Figure 3). 
 
The increase in tau expression likely results from a deregulated Nrf2/NDP52 pathway 
We next sought to determine the mechanisms by which tau is upregulated in CD. Using RT-
PCR, we found a decrease in tau mRNA in inflamed-CD samples as compared to controls 
(Figure 4A). In addition, we did not observe any difference between CD and controls when 
samples were analyzed by Western Blot for the amounts of TRIM 28, a transcriptional 
regulator that modulates both alpha-synuclein and tau levels (32) (Figure S4A). These results 
demonstrate that the higher amount of tau observed in CD does not result from an increase 
in tau transcription and suggest that other mechanisms such as modulation in tau 
proteostasis might be involved. A sizeable body of evidence have shown that tau could be 
degraded through the proteasome/ubiquitin pathway or turned over by the autophagy-
lysosome pathway (33). We first investigated the possible role of the proteasome/ubiquitin 
pathway by analyzing ubiquitin immunoreactivity in whole biopsy lysates by Western blot. 
The banding pattern was markedly different between CD and controls, with some stronger 
immunoreactive bands around 25, 35 and 50-60 kDa being observed in inflamed CD samples 
(Figure S4B). To further investigate the possible contribution of the proteasome to the 
degradation of tau in enteric neurons, we examined the levels of tau in primary culture of 
rat ENS in the presence of the proteasome inhibitor MG132. In line with our previous results, 
primary culture of rat ENS express four tau isoforms (0N3R, 1N3R/0N4R and 2N3R), which 
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migrate as a triplet of 50, 53 and 58 kDa bands on SDS PAGE (16). Treatment with MG132 
decreased the amount of all these tau isoforms (Figure S4C) thereby suggesting that 
proteasome inhibition is not involved in tau upregulation in enteric neurons.  
A recent study showed that the nuclear factor erythroid 2-related factor 2 (Nrf2) 
decreased the levels of tau by inducing the autophagy adaptor protein NDP52 (also known 
as CALCOCO2) in CNS neurons (34). When we analyzed the expression levels of Nrf2 and 
NDP52 in the GI tract, we found significantly lower amounts in CD inflamed samples (Figure 
4B). These findings suggest that a downregulation of the Nrf2/NDP52 pathway is involved in 
tau accumulation in CD inflamed segments. To further investigate the possible role of Nrf2 in 
enteric tau accumulation, we used a two-pronged approach. First, we treated primary 
culture of ENS with the Nrf2 activator sulforaphane. We showed that Nrf2 is primarily 
expressed by enteric glial cells and to a lesser extent by enteric neurons (Figure 5A) and that 
treatment with sulforaphane induced a significant decrease in the expression levels of all tau 
isoforms (Figure 5B), without changing its phosphorylation status (Figure 5B). Second, we 
performed additional experiments in Nrf2-knockout mice, which accumulate tau in their 
brains in an age-dependent manner (34). When we examined the levels of total and 
phosphorylated tau in the GI tissues of these mice, we observed a 2-fold increase in tau 
protein expression in the distal colon of 21-week-old Nrf2 knockout mice in comparison with 
wild-type mice (Figure 5D). No changes were observed in the distal colon of 11-week-old 
mice (Figure 5C). Tau phosphorylation levels were similar between Nrf2 knockout mice in 
comparison with wild-type mice, regardless of age (Figure 5C,D). Taken together, these 
findings show that tau upregulation in CD gut is not transcriptionally regulated but instead 
likely results from a decrease in protein clearance via an Nrf2 pathway. 
 
Alpha-synuclein and tau are similarly regulated in CD 
We previously used the colonic samples from 10/16 CD patients and 10/10 controls to show 
that alpha-synuclein was upregulated in CD inflamed area (18). We extend these previous 
findings by showing that alpha-synuclein mRNA expression is down-regulated in CD (Figure 
6A) and that it correlated with the amount of tau mRNA (Figure 6B). Such a positive 
correlation was also observed at the protein level (Figure 6C). Finally, we showed that, as 
with tau, treatment of primary culture of ENS with sulforaphane induced reduction of alpha-
synuclein and that the expression of alpha-synuclein was higher in the distal colon of 21-
 12 
week-old Nrf2 knockout mice when compared to wild-type mice (Figure 6D). Thus, alpha-
synuclein and tau are similarly regulated in CD gut. 
 
Discussion 
We have recently shown that the isoform profile of tau differed between the ENS and the 
CNS, with 1N3R and 0N4R being the two main tau isoforms expressed in adult human enteric 
neurons (16). In addition, we did not observe any changes in tau expression, 
phosphorylation or truncation of colonic samples from patients suffering from the 
prototypical tauopathy PSP. These results, along with the findings from a recent 
comprehensive autopsy survey (17) strongly suggest that unlike PD, the pathological process 
in tauopathies such as AD and PSP is limited to the CNS and does not involve the ENS. We 
therefore set out to examine the expression levels and phosphorylation state of tau in CD, 
an inflammatory bowel disease that has been consistently associated with ENS abnormalities 
(4). We found that the expression levels of enteric tau isoforms are dramatically increased in 
the colon of CD patients and that this upregulation is likely mediated through the 
Nrf2/NDP52 pathway. By contrast, no changes in the expression levels of tau was observed 
in UC.  
The ENS may be involved in inflammatory bowel disease as a result of tissue injury, or 
via the effects of soluble mediators of the inflammatory process including cytokines, 
arachidonic acid metabolites and oxygen-derived free radicals. Although changes in the 
morphology of the ENS have been described in both CD and UC, structural changes are more 
pronounced in CD than in UC (reviewed in (4, 35)). In this study, synapsin I, a neuronal 
phosphoprotein associated with the cytoplasmic surface of synaptic vesicles, was 
significantly decreased in samples of CD colon. These findings are in line with previous 
observations that showed severe and extensive submucosal axonal necrosis in the ileum and 
colon in CD but not in UC (36). This axonal necrosis may also explain the observed decrease 
in tau mRNAs, which are transported along the axon to be translated in situ in the axon 
terminals (37). 
Numerous proteases, such as aminopeptidases, calpains and caspases have been 
shown to proteolyze tau, however, most of these enzymes do not appear to be principally 
responsible for tau clearance. It is therefore unlikely that the sole decrease in tau truncation 
at Asp 421 in CD is sufficient to induce overexpression. The bulk of clearance of both 
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physiological and pathological forms of tau is instead mediated by the proteasomal and 
autophagic degradative systems (33, 38). While several reports suggested that tau could be 
degraded through the proteasome, others did not confirm this observation and even 
observed increased tau clearance in the presence of proteasome inhibitors in primary 
cortical neurons (34, 39). Our findings obtained in primary culture of ENS, which showed a 
decreased in tau in the presence of proteasome inhibitor MG132 are therefore in line with 
this latter observation. Although we could not exclude completely a role for other pathways, 
our data strongly indicate that the Nrf2/NDP52 autophagic pathway is involved in the 
accumulation of tau in CD (Figure 7). As the Nrf2 signaling system plays a key role in the 
maintenance of cellular homeostasis under stress, inflammatory, carcinogenic, and pro-
apoptotic conditions, it seems quite logical to observe a decreased expression of Nrf2 in CD 
(40). It should be however mentioned that, as far as we know, our study is the first to show 
that Nrf2 is downregulated in inflammatory bowel disease. Our observation reinforce the 
findings obtained in rodents, in which activating and/or upregulating Nrf2 alleviated DSS-
induced colitis (41, 42), thereby suggesting than reinforcing Nrf2 could be a potential 
therapeutic option for inflammatory bowel disease patients. 
Hyperphosphorylation, truncation and aggregation of tau are characteristic features 
of the pathological deposits observed in CNS tauopathies (38). Using specific antibodies and 
sequential extraction/ultracentrifugation, we did not find evidence of tau pathological forms 
in the inflamed zone in CD (we even observed a decrease in the amount of truncated tau). 
These findings are in keeping with the ones we obtained with alpha-synuclein, which is 
overexpressed but not aggregated in the ENS in CD (18, 43). One obvious limitation of our 
work is that the neuronal density in the ENS is rather low and that most of the analyses for 
the current study were essentially restricted to the analysis of the submucosal plexus. We 
can therefore not rule out that the absence of overt pathological changes in tau in colonic 
samples from our CD patients may be due to this limited regional analysis and perhaps 
different findings would have been obtained had we examined larger GI samples or used 
more sensitive approach such as protein misfolding cyclic amplification (44). 
The growing body of evidence suggesting that GI inflammation is involved in the 
development of PD recently led us to investigate the effects of inflammation on alpha-
synuclein expression in primary culture of rat ENS (23). We showed that two of the 
proinflammatory cytokines that are elevated in CD (Figure S1), namely TNF-α and IL-1β, 
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induced a downregulation of alpha-synuclein expression at both mRNA and protein levels in 
enteric neurons (23). Similar findings were observed when tau mRNA and protein were 
analyzed (our unpublished results). These observations are consistent with our current 
findings, which show a decrease of both alpha-synuclein and tau mRNA in the inflamed area 
in CD. They also suggest that the upregulation of alpha-synuclein and tau proteins in 
inflamed CD sample is not the mere consequence of inflammation on transcription and 
translation but likely results from a more complex process involving proteostasis regulation 
(Figure 7). 
Our current and previous findings demonstrate that both tau and alpha-synuclein, 
which are critically involved in neurodegenerative disorders are upregulated in CD further 
reinforcing the possible link between inflammatory bowel disease and neurodegenerative 
disorders (45). Some recent observations not only showed that PD and inflammatory bowel 
disease are epidemiologically (46) but also genetically linked. The Leucine-rich repeat kinase 
2 (LRRK2) gene, which has emerged as the gene most commonly associated with both 
familial and sporadic PD, has been subsequently identified by as a major susceptibility gene 
for CD  (21). Quite interestingly, molecular and neuropathological links between tau and 
LRRK2 have also been demonstrated: (i) LRRK2 binds to and phosphorylates tau (47, 48) (ii) 
tau is a prominent pathology in LRRK2 PD as well as in mice that overexpress mutated forms 
of LRRK2  (49, 50) (iii) LRRK2 promotes tau accumulation and aggregation and enhances the 
neuronal transmission of tau in the mouse brain (47, 51). It remains however to be 
determined why only a subset of patients with inflammatory bowel disease and GI 
inflammation will eventually develop a neurodegenerative disorder. A recent opinion paper 
has proposed that PD pathogenesis can be divided into three temporal phases: ‘triggers’, 
which set off the disease process in the brain and/or peripheral tissues, ‘facilitators’ that 
help triggers access the nervous system or spread the pathology within the CNS and 
‘aggravators’, which may for instance increase alpha-synuclein spreading (52). In such a 
scenario, it can be suggested that GI inflammation may act as a facilitator. 
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Name Specificity Epitope (a.a) Source and dilution 
A0024 Tau All tau isoforms 243-441 (2N4R)                                                          Dako, rp (WB 1:1,000; IHC 1:500) 
TAU-5 All tau isoforms 210- 241 (2N4R)                                                    ThermoFisher, mm (WB 1:1,000) 
Anti tau RD3             3R tau Isoforms                267-282 (2N3R)     Merck, mm, clone 8E6 (WB 1:1,000) 
Anti tau RD4               4R tau isoforms               275-291 (2N4R)                                                        Merck, mm, clone 1E1/A6 (WB 1:1,000) 
Anti tau T22 Tau oligomers               NS Merck, rp (WB 1:2,000; IHC 1:1,000) 
PHF13 Tau ℗ S396 Around Tau ℗ S396 Cell Signaling, mm (WB 1:1,000) 
Tau-421 Truncated tau Around D421 Merck, mm (WB 1:1,000) 
MAP2 MAP2 A,B,C,D NS Cell Signaling, rp (WB 1:1,000) 
Synapsin I Synapsin Around S9 Cell Signaling, rp (WB 1:2,000) 
-synuclein -synuclein NS Abcam, MJFR1, rm (WB 1:1,000) 
GFAP All GFAP isoforms Full length GFAP cow Dako, rp (IHC 1:5,000) 
Nrf2 Nrf2 aa 37-336 Santa Cruz, rp (IHC 1:500) 
III-tubulin βIII-tubulin 400 to C-terminus  Abcam, rm (WB 1:1,000, IF 1:500) 
PGP 9.5 UCHL1/PGP 9.5 15 aa near the C-terminus  Cedaralane, rp (WB 1:2,000) 
-actin -actin 16 aa, N-terminus Sigma, mm (WB 1:10,000) 
Table 1. The name, specificity, epitope, source and dilution of the antibodies used in this 
study are shown. Abbreviations are amino-acids (aa); immunohistochemistry (IHC); mouse 
monoclonal (mm); not specified (NS); rm (rabbit monoclonal); rabbit polyclonal (rp); western 
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blot (WB). 
 
Legends to figures 
Figure 1. Expression levels, phosphorylation state and truncation of tau protein in colonic 
biopsies from patients with Crohn’s disease. A, Colonic biopsy lysates from 16 Crohn’s 
disease (CD) patients and 16 controls (C) (see Figure S1 for subject details) were 
immunoblotted with total tau (TAU-5 IB), PGP 9.5 (PGP 9.5 IB) and -actin (-actin IB) 
antibodies. For CD patients, biopsies taken in non-inflammatory (NI, NI-CD) and 
inflammatory areas (I, I-CD) were analyzed separately. A representative immunoblot is 
shown (raw immunoblots are provided in Figure S2). Tau-immunoreactive bands were 
measured, normalized to the optical densities of PGP 9.5 and -actin and expressed as 
percentage of controls. Data correspond to mean ± SEM of 16 samples for C and CD, *** 
p<0.001 B, Representative immunoblots showing the expression of 3R and 4R tau using 
specific isoforms antibodies (8 CD and 8 C were analyzed) C, Colonic biopsies lysates from 10 
CD patients (#242, 243, 244, 248, 528, 539, 409, 461, 533 and 620) and 10 C (#190, 191, 192, 
193, 194, 195, 330, 344, 345 and 377) were immunoblotted with total tau (TAU-5 IB), tau 
phosphorylated at serine 396 (PHF13 IB), PGP 9.5 (PGP 9.5 IB) and -actin (-actin IB) 
antibodies. A representative immunoblot is shown (raw immunoblots are provided in Figure 
S2). Phosphorylated tau immunoreactive bands were measured, normalized to the optical 
densities of total tau and expressed as percentage of controls. Data correspond to 
mean ± SEM of 10 samples for Cand CD D, Colonic biopsies lysates from 16 CD and 16 C were 
immunoblotted with total tau (TAU-5 IB), truncated tau at Asp 421 (TAU-421) and PGP 9.5 
(PGP 9.5 IB) antibodies. In the upper panel, the membrane was probed with both TAU-5 and 
TAU-421 antibodies. A representative immunoblot is shown (raw immunoblots are provided 
in Figure S2). TAU-421 immunoreactive bands were measured, normalized to the optical 
densities of total tau and expressed as percentage of controls. Data correspond to 
mean ± SEM of 16 samples for CD and C, ** p<0.01. 
 
Figure 2. Localization and expression levels of tau in the myenteric plexus in Crohn’s 
disease and controls. A, Total tau antibody A0024 (Tau) was used to detect tau in the 
myenteric ganglia in 3 CD and 3 control subjects; beta III-tubulin (III-tub) antibody was used 
to specifically label neurons. Representative photomicrographs of one CD patient and one 
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control (C) are shown. Scale bar is 50 μm B, Quantitative analysis of tau immunofluorescence 
in the myenteric plexus of 3 C and 3 CD. Data are shown as corrected mean gray value 
normalized to controls and presented as mean ± SEM, n=18 and 17 myenteric ganglia for C 
and CD, respectively, **p < 0.01. 
 
Figure 3. Expression levels of MAP2c, synapsin I and -III tubulin in colonic biopsies from 
patients with Crohn’s disease. Colonic biopsy lysates from 6 CD patients (#242, 243, 244, 
248, 528 and 539) and 6 controls (C) were immunoblotted with MAP2c (MAP2c IB), synapsin 
I (Synapsin I IB) and -III tubulin (-actin IB) antibodies. MAP2c, synapsin I and -III tubulin 
immunoreactive bands were measured, normalized to the optical densities of PGP9.5 and 
expressed as percentage control. Data correspond to mean ± SEM of 6 samples for C and CD 
(*p<0.05) 
 
Figure 4. Transcriptional regulation of tau and Nrf2/NDP52 expression in Crohn’s disease. 
A, Quantitative PCR analysis of tau mRNA (MAPT) in colonic biopsy from all 16 CD patients 
(CD-NI and CD-I) and all 16 controls. Values represent mean ± SEM (n=16 samples per 
condition; *p<0.05) B, Expression levels of Nrf2 in CD. Colonic biopsy lysates from 8 CD 
patients (#242, 243, 244, 248, 517, 528, 539, 620) and 8 controls (C) were immunoblotted 
with Nrf2 (Nrf2 IB), NDP52 (NDP52 IB), PGP 9.5 (PGP 9.5 IB) and -actin (-actin IB) 
antibodies. Nrf2 and NDP52 immunoreactive bands were measured, normalized to the 
optical densities of PGP9.5 and expressed as percentage control. Data correspond to 
mean ± SEM of 8 samples for C and CD (*p<0.05) 
 
Figure 5. Role of Nrf2 in the regulation of enteric tau expression A, Distribution and 
localization of Nrf2 in primary ENS culture. Primary culture of rat ENS at 14 days in vitro were 
immunolabeled with anti-Nrf2, anti-III tubulin and anti-GFAP antibodies. Scale bar is 100 
µm for the upper panel and 50 µm for the lower panel B, Effects of sulforaphane on the 
expression levels of tau in primary culture of rat ENS. After 14 days in culture, primary 
culture of rat ENS were treated with vehicle (PBS, control) or 10 µM sulforaphane. Cell 
lysates were immunoblotted with total tau (A0024 Tau IB), tau phosphorylated at serine 396 
(PHF13 IB), PGP 9.5 (PGP 9.5 IB) and -actin (-actin IB) antibodies. Total tau and 
phosphorylated tau immunoreactive bands were measured, normalized to the optical 
 21 
densities of PGP9.5 and total tau, respectively and expressed as percentage of controls. 
Values represent mean ± SEM (n=8; treated versus control; **p<0.01) C, D, Distal colon 
lysates obtained from Nrf2-/- (11-week-old, two male and one female; 21-week-old, three 
male) or wild-type (WT, 11 months old, three male; 21-week-old, one female and two male) 
mice were immunoblotted with total tau (TAU-5 IB), tau phosphorylated at serine 396 
(PHF13 IB), PGP 9.5 (PGP 9.5 IB) and -actin (-actin IB) antibodies. Total tau and 
phosphorylated tau immunoreactive bands were measured, normalized to the optical 
densities of PGP9.5 and total tau, respectively and expressed as percentage of controls. 
 
Figure 6. Expression level of enteric alpha-synuclein and its correlation with tau. A, 
Quantitative PCR analysis of alpha-synuclein mRNA (SNCA) in colonic biopsy from 7 CD 
patients (CD-NI and CD-I, #248, 381, 409, 461, 539, 620) and 7 controls (#191, 194, 330, 335, 
345, 377 and 477) B, Correlation between SNCA and MAPT mRNA expression levels in 
colonic biopsy from 7 CD patients (CD-NI and CD-I, #248, 381, 409, 461, 539, 620) and 7 
controls (#191, 194, 330, 335, 345, 377 and 477) (r=0.73; p<0.0001) C, Correlation between 
alpha-synuclein and tau protein expression levels in colonic biopsy from 10 CD patients (CD-
NI and CD-I, #381, 387, 409, 436, 458, 461, 516, 517, 533 and 620) and 10 controls (#330, 
335, 344, 345, 359, 377, 428, 430, 450 and 456) (r=0.67; p<0.0001) D, Effects of 
sulforaphane on the expression levels of alpha-synuclein in primary culture of rat ENS. After 
14 days in culture, primary culture of rat ENS were treated with vehicle (PBS, control) or 10 
µM sulforaphane. Cell lysates were immunoblotted with alpha-synuclein (Syn IB), PGP 9.5 
(PGP 9.5 IB) and -actin (-actin IB) antibodies. Alpha-synuclein immunoreactive bands were 
measured, normalized to the optical densities of PGP9.5 and expressed as percentage of 
controls. Values represent mean ± SEM (n=6; treated versus control; *p<0.05) E, Distal colon 
lysates obtained from Nrf2-/- (21-week-old, three male) or wild-type (WT; 21-week-old, one 
female and two male) mice were immunoblotted with alpha-synuclein (Syn IB), PGP 9.5 (PGP 
9.5 IB) and -actin (-actin IB) antibodies. Alpha-synuclein immunoreactive bands were 
measured, normalized to the optical densities of PGP9.5 and expressed as percentage of 
controls. 
 
Figure 7. Proposed mechanisms for increased tau and alpha-synuclein expression in enteric 
neurons in CD. In the gut and more specifically in the ENS, both tau and alpha-synuclein are 
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abundantly expressed in enteric neurons. Our current and previous findings show that, 
despite a decrease in their mRNA levels, both tau and alpha-synuclein proteins are 
upregulated in the ENS of CD patients. We propose that the decrease in mRNA observed in 
CD is counterbalanced and even overwhelmed by a marked fall in the degradation of both 
proteins (at least in part via a decreased activity of the Nrf2/NDP52 autophagic pathway), 
resulting in tau and alpha-synuclein proteins accumulation. Motifolio drawing toolkits 
(http://www.motifolio.com/) were utilized in the figure. 
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Figure 7
Patient # Diagnosis Age Sex Disease duration (y) Treatment 
242 CD 23 F 6 IMS 
243 CD 52 F 8 cortico + 5-ASA 
244 CD 31 M 3 IMS 
248 CD 45 F 22 antiTNF 
381 CD 34 M 8 IMS 
387 CD 43 F UNK antiTNF 
409 CD 34 M UNK antiTNF 
436 CD 20 M 6 antiTNF 
458 CD 38 F UNK None for 2 years 
461 CD 35 M 6 antiTNF 
516 CD 39 M 18 antiTNF - IMS 
517 CD 22 M 8 antiTNF 
528 CD 21 F 9 5-ASA 
533 CD 24 M 7 antiTNF - IMS 
539 CD 39 M 19 antiTNF+ IMS 
620 CD 38 F 12 None for 2 years 
283 UC 31 F 11 5-ASA 
429 UC 45 M UNK IMS 
438 UC 36 F 6 5-ASA 
494 UC 37 F 3 antiTNF 
504 UC 49 M 13 antiTNF - 5-ASA 
586 UC 38 M 4 antiTNF - 5-ASA 
190 Control 51 M - - 
191 Control 64 M - - 
192 Control 70 F - - 
193 Control 72 F - - 
194 Control 63 F - - 
195 Control 61 F - - 
330 Control 55 M - - 
335 Control 73 F - - 
344 Control 41 F - - 
345 Control 48 F - - 
377 Control 48 F - - 
430 Control 41 F - - 
450 Control 49 M - - 
456 Control 47 F - - 
460 Control 31 F - - 
477 Control 18 F - - 
Supplementary Figure 1. A, Quantitative PCR analysis of IL1-b and TNF-a mRNA in colonic 
biopsy from all 16 CD patients (CD-NI and CD-I), all 6 UC patients (UC-NI and UC-I) and all 16 
controls. Values represent mean ± SEM (*p<0.05 ; ***p<0.001) B, Subjects’ demographics and 
treatments. 5-ASA: 5-aminosalicylic acid; anti-TNF: anti-TNF-a; cortico: corticosteroids; IMS: 
immunosuppressive therapy; UC: ulcerative colitis; UNK: unknown. CD patients were 
significantly younger than controls (Age, mean +/- SD 33.6 +/- 9.5 vs 52.0 +/- 15.1, p< 0.001) 
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Supplementary Figure 2. Raw immunoblot data for CD and UC patients and quantification for UC patients. No correlation was observed 
between the amount of tau (Tau5/PGP 9.5) and age (Table S1) for CD, rs=0.39; p=0.15. No correlation was observed between the amount of tau 
(Tau5/PGP 9.5) and disease duration (Table S1) for CD, rs=0.17; p=0.57  
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Supplementary figure 3. Analysis of sarkosyl-insoluble tau and oligomeric forms of tau in colonic biopsies from patients with Crohn’s disease. (a) Lysates from control (C) and 
Alzheimer’s disease (AD) brains served as controls to ensure that the immunoreactive pattern observed with T22 was different in AD brain when compared to control brain. (b) 
Colonic biopsy lysates from 3 CD patients (#517, 539 and 620) and 3 controls (C) were subjected to immunoblot analysis using Tau T22 antibody (c and d) Full thickness segments 
of colon from 2 CD and 2 controls along with samples of control (C) and Alzheimer’s disease (AD) brains were separated into sarkosyl-soluble and insoluble fractions as described in 
the methods and in the diagram. Tau was analyzed by immunoblotting using Tau T22. 
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Supplementary Figure 4. A, Expression levels of TRIM28 in Crohn’s disease. Colonic biopsy lysates from all 16 CD patients and all 16 controls were immunoblotted with 
antibodies against TRIM28 (TRIM28 IB), PGP 9.5 (PGP 9.5 IB) and b-actin (b-actin IB). TRIM28 immunoreactive bands were measured, normalized to the optical densities of 
PGP 9.5 and expressed as a percentage of the average of controls. B, Representative immunoblots of ubiquitin levels in biopsy lysates from CD patients and control subjects. 
The arrows show some of the bands whose levels varied between CD and controls. C, Primary culture of rat ENS were treated or not with 10 µM MG132 for 12h and 15 µg of 
cell lysates were subjected to immunoblot analysis using A0024 Tau, PGP 9.5 (PGP 9.5 IB) and b-actin (b-actin IB) antibodies. 
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